Status:
COMPLETED
Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Pain
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the pharmacokinetic drug-drug interactions, safety, and tolerability of co-administration of VX-993 and metformin in healthy participants.
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable ...
Eligibility Criteria
Inclusion
- Key
- Body mass index (BMI) of 18.0 to 32.0 Kilogram per square meter (kg/m\^2)
- A total body weight of more than (\>) 50 Kg
- Nonsmoker or ex-smoker for at least 3 months before the first study drug dose
- Key
Exclusion
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
July 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT06523595
Start Date
July 31 2024
End Date
December 31 2024
Last Update
January 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICON Salt Lake City
Salt Lake City, Utah, United States, 84124